Division of Dermatology, Department of Medicine, National University Hospital, Singapore, Singapore.
Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
Australas J Dermatol. 2023 May;64(2):e152-e159. doi: 10.1111/ajd.13987. Epub 2023 Feb 2.
Erythroderma is an inflammatory skin condition that causes extensive erythema and skin scaling amounting ≥90% of the body surface area. This retrospective cohort study describes the prevalence of malignancy-associated erythroderma in a single centre where there was concerted effort to systematically offer malignancy screens to all adult erythroderma patients above the age of 65 years.
Clinical charts were reviewed for all adult inpatients and outpatients with erythroderma who attended the National University Hospital (NUH) from 1 July 2019 to 31 December 2021. Data collected included patient demographics, clinical findings, laboratory investigations, disease-specific investigations such as endoscopic procedures and biopsies, follow-up duration and mortality data.
Seventy-four patients were analysed. The median age of the patients was 73 years old (interquartile range: 59-81 years old). An underlying dermatosis was the most common cause of erythroderma-63 patients having atopic dermatitis/asteatotic eczema or psoriasis. Three patients had erythroderma from drug eruptions, and 1 patient had chronic actinic dermatitis. Four patients had associated malignancies (5.4%). Half of our patients completed further evaluation for malignancy (52.7%). The rest had either declined or were eventually unable to complete the investigations. There was a higher prevalence of associated malignancy (7.8%) in elderly patients above 65 years old.
When compared to existing literature, our cohort reflects a higher observed occurrence of malignancy in association with erythroderma. As delays in evaluation for underlying malignancy could result in potentially deleterious outcomes, it is prudent to consider systematic screening for malignancy in high-risk populations such as elderly erythroderma patients.
红皮病是一种炎症性皮肤病,可导致广泛的红斑和皮肤脱屑,面积≥90%的体表面积。这项回顾性队列研究描述了在一个中心,对所有 65 岁以上的成人红皮病患者系统地进行恶性肿瘤筛查时,与恶性肿瘤相关的红皮病的患病率。
对 2019 年 7 月 1 日至 2021 年 12 月 31 日期间在新加坡国立大学医院(NUH)就诊的所有成人住院和门诊红皮病患者的临床病历进行了回顾。收集的数据包括患者人口统计学、临床发现、实验室检查、疾病特异性检查(如内镜检查和活检)、随访时间和死亡率数据。
共分析了 74 例患者。患者的中位年龄为 73 岁(四分位距:59-81 岁)。最常见的红皮病病因是皮肤病,有 63 例为特应性皮炎/非脂溢性湿疹或银屑病。3 例因药物反应出现红皮病,1 例为慢性光化性皮炎。4 例患者合并恶性肿瘤(5.4%)。我们有一半的患者完成了进一步的恶性肿瘤评估(52.7%)。其余的要么拒绝,要么最终无法完成检查。65 岁以上的老年患者合并恶性肿瘤的患病率(7.8%)更高。
与现有文献相比,我们的队列反映了与红皮病相关的恶性肿瘤发生率更高。由于延迟评估潜在恶性肿瘤可能导致潜在的有害后果,因此在老年红皮病患者等高危人群中,考虑系统筛查恶性肿瘤是谨慎的。